Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, Canada, Japan, China, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Læs mere